UltraSound - Technology Information PortalWednesday, 1 March 2017
Info
  Sheets



Out-
      side
 




 
 'drug information and specification' 
SEARCH FOR   
 
  12345ABCDEFGHIJKLMNOPQRSTUVWZ
Result : Searchterm 'drug information and specification' found in 0 term [] and 19 definitions [], (+ 1 Boolean[] results)
1 - 5 (of 20)     next
Result Pages : [1 2 3 4]
US Resources  
Software - Prenatal - DICOM - Examinations - Equipment and Parts - Services and Supplies
 
AI-700InfoSheet: - Contrast Agents - 
Intro, 
Historical Development, 
Microbubbles,
etc.MRI Resource Directory:<br> - Contrast Agents -
 
From Acusphere Inc
AI-700 is an US contrast agent, usable for myocardial perfusion undergoing regulatory FDA approval. The synthetic polymers used in AI-700 do not break during the ultrasound imaging procedure. The used perfluorocarbon filling gas is less soluble in water and therefore has the propensity to stay inside the contrast agent particles. As a result, a higher concentration of gas is delivered to the myocardium over a longer period of time, thereby enabling AI-700 to target the broader application of myocardial perfusion assessment.
AI-700 is a dry powder consisting of small, porous microparticles filled with perfluoropropane. These microparticles are made of a synthetic biodegradable polymer, called poly (D, L-lactide co-glycolide), or PLGA, that has been used in other drug delivery systems approved by the FDA.
The composition and structure of the phospholipid containing microparticles and the properties of the perfluorocarbon gas slow the rate at which the gas dissolves and prevent the microparticles from being quickly broken down. The powder is to suspend in sterile water and injected by a single intravenous injection prior to ultrasound imaging.

In June 2004, Acusphere entered into a Collaboration, License and Supply Agreement with Nycomed Danmark APS for the European development and marketing rights to Acusphere’s lead product candidate AI-700.
Nycomed will be responsible for sales, marketing and the regulatory submissions required for marketing throughout its sales territory, which includes the member states of the European Union, as well as Russia/CIS and the Baltic States.

Drug Information and Specification:
RESEARCH NAME AI 700
DEVELOPER Acusphere, Inc.
INDICATION -
DEVELOPMENT STAGE
myocardial perfusion
APPLICATION Intravenous injection
TYPE Microbubble
SHELL Poly-L-lactide co glycolide
CHARGE Negative
GAS Perfluorocarbon
MICROBUBBLE SIZE -
PREPARATION Reconstitute with water
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer

• View the news results for 'AI-700' (3).


• Related Searches:
    • Urologic Ultrasound
    • SONOVET 600
    • Gray Scale
    • Logarithms
    • SONOLINE Omnia

 Further Reading:
  News & More:
Acusphere's AI-700 Pilot Study Exceeds ExpectationsOpen this link in a new window
Thursday, 6 January 2005   by www.thefreelibrary.com    
Acusphere Reaches AI-700 Clinical Trial Milestone; 300 Patients Enrolled in Phase 3 Clinical ProgramOpen this link in a new window
Thursday, 16 December 2004   by phx.corporate-ir.net    
A Method for Radiation-Force Localized DrugDelivery Using Gas-Filled Lipospheres(.pdf)Open this link in a new window
Wednesday, 7 July 2004   by www.ncbi.nlm.nih.gov    
Acusphere Completes Enrollment in Second Phase 3 ClinicalOpen this link in a new window
Friday, 5 May 2006   by phx.corporate-ir.net    
US Resources  
Gynecology - Portable UltraSound - Kidney - RIS - Online Books - UltraSound Reimbursement
 
AlbunexInfoSheet: - Contrast Agents - 
Intro, 
Historical Development, 
Microbubbles,
etc.MRI Resource Directory:<br> - Contrast Agents -
 
Albunex and Infoson, used mainly in cardiac evaluations, are first generation one-pass-only contrast agents and have been replaced by the new-generation contrast media. Albunex and Infoson are the same sonicated human serum albumin microbubbles. Infoson is licensed and manufactured in Europe, while Albunex was produced in the USA.
Albunex, an air-filled microbubble with a denatured albumin shell (modified from air-filled albumin microspheres prepared from sonicated 5% human serum albumin), was the first FDA-approved contrast agent, but is no longer in production.
Cardiac shunts and valve regurgitations are often evaluated with Color Doppler Imaging (CDI), which also improved with injections of Albunex, but this agent is pressure-sensitive and does not recirculate. It is effectively a one-pass-only agent, limiting its clinical efficacy.
See also First generation USCA, Echocardiography and Contrast Enhanced Ultrasound.
Drug Information and Specification:
DEVELOPER Mallinckrodt Inc.
INDICATION Contrast sonography and Doppler-echocardiography
APPLICATION Intravenous injection
TYPE Microbubble
SHELL - STABILIZATION Albumin
GAS Air
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer

 Further Reading:
  News & More:
molecular imaging using ultrasoundOpen this link in a new window
   by bjr.birjournals.org    
Detecting and Imaging Microbubble contrast agents with ultrasoundOpen this link in a new window
2000   by www.collectionscanada.ca    
US Resources  
Safety - Databases - Vaginal - Ultrasound Therapy - Obstetric - Preferential Sites
 
BG1135InfoSheet: - Contrast Agents - 
Intro, 
Historical Development, 
Microbubbles,
etc.MRI Resource Directory:<br> - Contrast Agents -
 
From Bracco Research S. A., Geneva, Switzerland
BG1135 is a polymer-shelled new ultrasound contrast agent under development. The air-filled microsphere has a rigid, 100 nm thick polymeric shell and a mean diameter of 2.9 mm with 99% less than 8 mm.
The destruction mechanism of BG1135 is unique among microbubbles. The microbubbles of BG1135 appear to acquire a small shell defect, allowing the filling gas to stream out and creating a new gas bubble, but leaving the old shell intact. No significant differences between the diameters of the shells can be measured before and after insonation even though the agent is fragmented.

Drug Information and Specification:
RESEARCH NAME BG1135
DEVELOPER Bracco Diagnostics, Inc.
DEVELOPMENT STAGE Preclinical
APPLICATION Intravenous
TYPE Microbubble
SHELL Polymer
GAS Air
MICROBUBBLE SIZE Mean diameter: 2.9 µm
99% < 8µm
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer

 Further Reading:
  Basics:
Optical observation of lipid- and polymer-shelled ultrasound microbubble contrast agentsOpen this link in a new window
   by escholarship.org    
US Resources  
UltraSound Reimbursement - Corporations - Contrast Agents - Endoscopic - Vaginal - Liver
 
BR14InfoSheet: - Contrast Agents - 
Intro, 
Historical Development, 
Microbubbles,
etc.MRI Resource Directory:<br> - Contrast Agents -
 
From Bracco Research SA, Geneva, Switzerland,
BR14 is a new experimental ultrasound contrast agent, consisting of bubbles containing a high molecular weight filling gas enclosed by a flexible phospholipid monolayer shell a few nanometers thick.
This agent shows significant non-linear scattering and agent modification even at low insonation pressures, the detection pulses used did not destroy the contrast bubbles. The results obtained with HPD before the release burst show that the BR14 bubbles are efficient scatterers that can be modified and, thus, detected by low power insonation.

Drug Information and Specification:
RESEARCH NAME BR14
DEVELOPER Bracco Diagnostics, Inc.
DEVELOPMENT STAGE Preclinical
APPLICATION -
TYPE Microbubble
SHELL -
CHARGE Negative
GAS Perfluorobutane
MICROBUBBLE SIZE Mean size 3µm, 95% < 10µm
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer

 Further Reading:
  News & More:
The role of ultrasound in molecular imaging(.pdf)Open this link in a new window
2003   by bjr.birjournals.org    
US Resources  
Renal - Pregnancy - Portable UltraSound - Quality Advice - Veterinary UltraSound - Pelvic
 
CARDIOsphere®InfoSheet: - Contrast Agents - 
Intro, 
Historical Development, 
Microbubbles,
etc.MRI Resource Directory:<br> - Contrast Agents -
 
From POINT Biomedical Corp
CARDIOsphere® is an ultrasound contrast agent for assessment of myocardial perfusion in patients with coronary artery disease composed of highly echogenic bispheres.
PB127 is a new developed microbubble with a bilayer polymer/albumin shell filled with nitrogen gas that has ideal characteristics for power harmonic Doppler. They can be destroyed by high power ultrasound, and spectral decorrelation between ultrasound pulses is maximized by rapid dissolution of the released nitrogen gas.
POINT Biomedical Corp. announced (March 01, 2004) that it has completed two Phase 3 trials of CARDIOsphere®. The Phase 3 trials were designed to evaluate the performance of CARDIOsphere® imaging relative to radionuclide imaging for detecting obstructive coronary artery disease and identifying the anatomic location of perfusion defects.

Drug Information and Specification:
RESEARCH NAME PB 127
DEVELOPER Point Biomedical Corp.
INDICATION -
DEVELOPMENT STAGE
Myocardial perfusion -
Phase 3 completed
APPLICATION Infusion
TYPE Microbubble
SHELL Polylactide/Albumin
CHARGE Slight Negative
GAS Nitrogen
PREPARATION Reconstitute with 2ml H2O per vial and dilute with 150 ml DSW
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

spacer

• View the news results for 'CARDIOsphere®' (2).



US Resources  
Gall Bladder - Software - - Portals - Abdominal - Preferential Sites
 
Related Searches:
 • EUB-500
 • Run-time Artifact
 • Power Mode
 • Guerbet S.A.
 • A-Scan
SEARCH FOR   
 
  12345ABCDEFGHIJKLMNOPQRSTUVWZ
     1 - 5 (of 20)     next
Result Pages : [1 2 3 4]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

US-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  


Look
      Ups



UltraSound - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2006 - 2016 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertising
 [last update: 2015-03-04 09:17:02]